Literature DB >> 12766845

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.

Angela Ma Tobón1, Myrtha Arango, Darío Fernández, Angela Restrepo.   

Abstract

We describe the case of a diabetic patient who developed a severe invasive fungal infection due to Rhizopus species postoperatively after a dual heart/kidney transplantation with subsequent intensive immunosuppressive therapy. No improvement was noted with amphotericin B (deoxycholate) therapy, but salvage treatment with the new azole antifungal posaconazole (200 mg orally 4 times daily) resulted in dramatic clinical improvement as early as 1 week after the initiation of therapy that continued through 23 weeks of treatment, with marked clinical, mycological, and radiological improvements and no adverse events.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766845     DOI: 10.1086/375075

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Gastrointestinal zygomycosis complicating heart and lung transplantation in a patient with Eisenmenger's syndrome.

Authors:  Pavan Manchikalapati; Cheri L Canon; Nirag Jhala; Mohamad A Eloubeidi
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

3.  Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue.

Authors:  R Bialek; F Konrad; J Kern; C Aepinus; L Cecenas; G M Gonzalez; G Just-Nübling; B Willinger; E Presterl; C Lass-Flörl; V Rickerts
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 6.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

7.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

8.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

Authors:  M Mar Rodríguez; Enrique Calvo; Marçal Mariné; F Javier Pastor; Joan Fernandez-Ballart; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.